Document 995B4Nqxd48MbdDOEkqXjnzb7

. . "SaiLatrrMyVeiRs.e;ZPobDielo,onMrD, MPH 3M Medical Department AR 226 -- 108.2 P3OMBrCoaexnite3wr3,i2sB20iskmisngo0m220-02602 6157173333 55582OFfxfice 324pf EHR ~0302 _00373 3 AM oer LEHp - Bo- 372 gto om WR 5735Q Co Document Processing Center (7407) OAfTfTiNc:e ofScPcotlliuotnio8n(,c)PrCeovoerndtiinoantoarnd Toxics US 401 Environmental M Street, SW Protection Agency Washington, D.C. 20460 Cc Z ONtain No Cay FRel:uorToSchCeAmi8c(ael)sS-upDpolcekmeetntNaulmNboetrisce8EfoHrQ-S1ul1f8o0n-a3t7e3-:basSeEdHaQn-d11C8ar0b-o3x7y4l:icS-EbHasQe-d03810394; SEHQ-0598-373 Dear Docket Coordinator: rWeiltathedthtiso lpertetevri,o3usMTiSsCprAovSiedcitnigonfi8n(ael)rneoptoirftiscaatniodnso.theArllsoupfptlheemeenntcallosiendfoirtmemastiaorne already in EPA's possession and available in TSCA Docket AR-226. We believe, however, that placing these items in the 8(e) docket may allow for more convenient access to information directly related to previous 8(e) notifications by 3M. "The reports enclosed are as follows: 1. Final Report, IdentificationofFluorochemicals in Human Sera. Red Cross Adult Blood Donors, February 25, 2002. 1. American 2. PFianratlicRiepapnotrst,ofItdhenetiAfdiuclattiConhaonfgFelsuoirnocThheomuigchatlsStiundyH.uSmeaatntleSe.raW.ash11i. ngEtlodne.rly February 25. 2002. 3. PFianratlicRiepapnotrst,inIdaenGtriofuicpatAionSotfreFpltuoocrooccciheCmliinciaclasl TirniHaluImnavnestSiegraa.tioInl,l.MaPredcihatr1i5.c 2002 4. Interim Report #2. Determination of Fluorochemicals, January 11. 2002. Serum Half-Lives of Several & Epa-oTs = gs 3 3 25 3289 =z> 3555 > = 0008118442 | 000001 March 19,2002 Page 2 5. F(iPnFaOlSR)epaonrdt,PeArfLlounogriotoucdtiannaolatAena(lPyFsOisAo)fiSneRreulamtiPoenrftlouColrionoicctaalnCehseulmfiosntartye, TEhmyprlooiydeHeoPramrotincei,paHntesmoaftotlheog2y00a0ndAnUrtiwnearlpysainsdReDseuclattsurfrFolmuoMraolceheamnidcaFlemale Medical Surveillance Program, October 11, 2001. 6. (FiPnFaOlSR)epaonrdt,PeArfLlounogriotoucdtiannaolatAena(lPyFsOisAo)fLSeevrelusmiPneRrefllautoiroonocttoaLniepsiudlfaonndate Htheepa1t9i9c4/C9l5in,ic1a9l97Chaenmdis2t0r0y0TFelsutoRreoscuhletmsicfarlomMeMdailcealEmSpurlvoeyielelaPnacretPicriopgarnatms,of October 11,2001 cIanlaedudliattieobn,en3cMhmcaornktrdaocsteesd wfiorthloDwr.-dDoasveicdaGncaeyrlorrisokfaSscsieesnscmeesntInbtaesrenadtoionnatlh,eIrnec.sulttos rferpoomrttshewecraencseurbbmiiotatsesdaoyns Finebrratusarwyit8h, N20-0E2{.FODSr.EGaaynldoPr'FsOSr.eporTthsesperotvwiod-eyveaalrubeisofaosrsay dtiheetalroywecron9c5e"ntpreartcieonntocfoNnf-iEd{eFncOeSElimoirtoPfFOtShe, breesnpcehcmtiavrektdootshee (tesBt McoDmjopL)ouinndteursmesdofin the study, and serum PFOS concentration, as measured at 1d-weeksofdosing. 7. BPeernfclhumoarorokctDaonseessulffoornTaumimdoorEitnhaSnporlag(uNe-ED(aFwOlSeEy),RaJtasnufaedryN-3E1,th2y0l02. 8. BPeernfclhumoraorokctDaonseeSsulffoornLiicveArciTdumPootrassisniuSmprSaalgtue(PDFaOwSl)e,yJaRnautasrfyed24, 2002. Please contact Dr. John Butenhoft, 651-733-1962, for further information on these studics. or Dr. Geary Olsen, 651-737-8569, Regards, Larry R. Zobel, MD MPH StaffVice President & Medical Director ce: JL. Butenhof-f 220-2E-02 G.W. Olsen - 2203W-05 2 000002